- 06:26 PM MFs net sell Rs 176 cr in equities on Nov 19
- 06:05 PM Be invested in Sun Pharma, Cipla, Dr Reddy’s: Sukh...
- 05:59 PM Tata Equity P/E Fund declares Dividend
- 05:52 PM Bharti Airtel has support at Rs 190-200: Sukhani
- 05:48 PM What does PM's Afghan comment mean for India-Pak p...
- 05:37 PM Buy hotel stocks on correction: Sukhani
- 05:35 PM Buy NIIT Tech on dips; avoid Patni: Sudarshan Sukh...
- 05:35 PM UTI Services Industries Fund declares dividend
- 05:34 PM IMF official warns of bubbles in emerging markets
- 05:33 PM McNally Bharat says current orderbook at Rs 31 bn



Religare has maintained buy rating on Glenmark Pharma with target price of Rs 716, in its June 16, 2008 report. "A leading Indian company to focus on and unlock value from NCE research. Maturing R&D pipeline of eight NCEs and five NBEs, which we have valued at Rs 220/share. Enjoys a wide geographical spread in conjunction with a strong product pipeline for the US and RoW markets. Employing the inorganic route to gain scale in Europe. We have valued the generic business at Rs 496/share. Valuation Strong earnings growth expected as the generic business gains scale. Will continue to benefit from progressive monetising of its R&D pipeline. We have an SOTP-based target price of Rs 716 for the stock" says Religare report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
For further details click on attachment......
Attachments : Market Outlook - Value Picks16Jun08.pdf |
|
Stock Advice
|
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- Corrections in '10 to be more aggressive, violent: JPMorgan

- 10 companies that MF managers love
- Bollywood actress Shilpa Shetty marries Raj Kundra
- LyondellBasell development positive for RIL: PN Vijay

- Ignore Buffett, gold`s time has come
- Shilpa Shetty marries Raj Kundra
- Ganeshaspeaks: Market prediction for Nov 23
- MFs net sell Rs 176 cr in equities on Nov 19
Source: Moneycontrol.com
- Be invested in Sun Pharma, Cipla, Dr Reddy’s: Sukhani
Source: CNBC-TV18
- Tata Equity P/E Fund declares Dividend
Source: Moneycontrol.com
- Bharti Airtel has support at Rs 190-200: Sukhani
Source: CNBC-TV18
- China`s Haitong Securities buys Hong Kong rival
Source: ft.com
- KSIDC in pact with FACT for trade centre
Source: Business Line
- GIC Re may have to pay Rs100cr for IOC's Jaipur fire claims
Source: Business Line
- Co-operative dairies seek restraint on oil-meal exports
Source: Business Line






















